We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy and Safety of S18986 in the Treatment of Mild Cognitive Impairment Patients

This study has been terminated.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00202540
First Posted: September 20, 2005
Last Update Posted: October 20, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Servier
  Purpose
The purpose of this study is to demonstrate a long term efficacy of S18986 versus placebo on episodic memory performance in patients with MCI

Condition Intervention Phase
Mild Cognitive Impairment Drug: S18986 Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Official Title: Efficacy of 15 mg and 50 mg of S18986 on Cognitive Symptoms in Mild Cognitive Impairment Patients Treated Over a 12-month Oral Administration Period

Further study details as provided by Servier:

Primary Outcome Measures:
  • Episodic memory

Secondary Outcome Measures:
  • Other cognitive domains, activities of daily living, global impression of change, MRI, safety.

Enrollment: 38
Study Start Date: June 2005
Study Completion Date: March 29, 2006
Primary Completion Date: March 29, 2006 (Final data collection date for primary outcome measure)
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   55 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Memory complaint
  • Acetylcholinesterase inhibitors stopped at least 3 months before selection

Exclusion Criteria:

  • Dementia
  • Parkinson's disease
  • Vascular disorder
  • Depression
  • Epilepsy
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00202540


Locations
France
Hôpital la Grave-Casselardit
Toulouse, France, 31000
Sponsors and Collaborators
Institut de Recherches Internationales Servier
Investigators
Study Chair: Bruno Vellas, MD Hôpital la Grave-Casselardit, Toulouse
  More Information

Additional Information:
ClinicalTrials.gov Identifier: NCT00202540     History of Changes
Other Study ID Numbers: CL2-18986-009
First Submitted: September 12, 2005
First Posted: September 20, 2005
Last Update Posted: October 20, 2017
Last Verified: April 2017

Additional relevant MeSH terms:
Cognitive Dysfunction
Cognition Disorders
Neurocognitive Disorders
Mental Disorders